Omitting breakfast and lunch after injection of different long-acting insulin preparations at bedtime: A prospective study in patients with type 2 diabetes

Diabetologia

Volumn 52, Issue 9, 2009, Pages 1816-1819

  Wiesli, P ^a   Krayenbuhl P ^b   Uthoff, H ^a   Seifert, B ^c   Schmid, C ^b  

^a Kantonsspital Frauenfeld   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Insulin detemir; Insulin glargine; NPH insulin; Type 2 diabetes

Indexed keywords

C PEPTIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; LONG ACTING INSULIN;

ADULT; AGED; ARTICLE; BEDTIME DOSAGE; BLOOD GLUCOSE MONITORING; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE DURATION; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; MALE; MEAL; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TREATMENT DURATION;

AGE OF ONSET; AGED; BLOOD GLUCOSE; C-PEPTIDE; CREATININE; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; FASTING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN, LONG-ACTING; INSULIN, NPH; MALE; MIDDLE AGED;

EID: 68449085005     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-009-1439-z     Document Type: Article

References (10)

1. T Heise L Nosek B Rønn 2004 Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes Diabetes 53 1614 1620
2. J Plank M Bodenlenz F Sinner 2005 A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir Diabetes Care 28 1107 1112
3. Lepore M, Pampanelli S, Fanelli C, et al 2000 Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro Diabetes 49 2142 2148
4. S Swinnen F Holleman J DeVries 2008 The interpretation of glucose clamp studies of long-acting insulin analogues: from physiology to marketing and back Diabetologia 51 1790 1795
5. F Holleman E Gale 2007 Nice insulins, pity about the evidence Diabetologia 50 1783 1790
6. B Trümper K Reschke J Molling 1995 Circadian variation of insulin requirement in insulin dependent diabetes mellitus the relationship between circadian change in insulin demand and diurnal patterns of growth hormone, cortisol and glucagon during euglycemia Horm Metab Res 27 141 147
7. E Shapiro K Polonsky G Copinschi 1991 Nocturnal elevation of glucose levels during fasting in noninsulin-dependent diabetes J Clin Endocrinol Metab 72 444 454
8. P Wiesli R Lehmann P Krayenbuehl C Schmid G Spinas 2006 Assessment of basal insulin requirement using fasting tests in insulin-treated patients with type 2 diabetes mellitus Exp Clin Endocrinol Diabetes 114 539 543
9. D Cockcroft M Gault 1976 Prediction of creatinine clearance from serum creatinine Nephron 16 31 41
10. L Heinemann R Linkeschova K Rave B Hompesch M Sedlak T Heise 2000 Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo Diabetes Care 23 644 649